Clinical pharmacology of the novel marine-derived anticancer agent Ecteinascidin 743 administered as a 1- and 3-h infusion in a phase I study

Anti-Cancer Drugs

Volumn 13, Issue 4, 2002, Pages 381-393

  Van Kesteren, Charlotte ^a   Twelves, Chris ^a   Bowman, Angela ^a   Hoekman, Klaas ^a   López Lázaro, Luis ^a   Jimeno, José ^a   Guzman, Cecilia ^a   Mathôt, Ron A A ^a   Simpson, Andrew ^a   Vermorken, Jan B ^a   Smyth, John ^a   Schellens, Jan H M ^a   Hillebrand, Michel J X ^a   Rosing, Hilde ^a   Beijnen, Jos H ^a  

^a SLOTERVAART HOSPITAL   (Netherlands)

Author keywords

ET 743; Pharmacodynamics; Pharmacokinetics; Phase I study

Indexed keywords

ANTINEOPLASTIC AGENT; TRABECTEDIN;

ADULT; AGED; AREA UNDER THE CURVE; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG ELIMINATION; DRUG HALF LIFE; FATIGUE; FEMALE; HUMAN; LIVER TOXICITY; MALE; MARINE ENVIRONMENT; MAXIMUM TOLERATED DOSE; PANCYTOPENIA; PHASE 1 CLINICAL TRIAL; PRIORITY JOURNAL; SOLID TUMOR; THROMBOCYTOPENIA;

ADULT; AGED; ANIMALS; ANTINEOPLASTIC AGENTS, ALKYLATING; AREA UNDER CURVE; DIOXOLES; FATIGUE; FEMALE; HALF-LIFE; HUMANS; INFUSIONS, INTRAVENOUS; ISOQUINOLINES; MALE; MAXIMUM TOLERATED DOSE; MIDDLE AGED; TETRAHYDROISOQUINOLINES; THROMBOCYTOPENIA; TIME FACTORS; UROCHORDATA;

EID: 0036239748     PISSN: 09594973     EISSN: None     Source Type: Journal    
DOI: 10.1097/00001813-200204000-00007     Document Type: Article

References (28)

1. Progress in the acquisition of new-marine-derived anticancer compounds: Development of ecteinascidin-743 (ET-743)
2. Some hope from marine derived natural products
3. Pharmaceutical development of anticancer agents derived from marine sources
4. Antitumor compounds from tunicates
5. In vitro antitumor activity of the novel marine agent, Ecteinascidin-743 (ET-743, NSC-648766) against human tumors explanted from patients
6. Ecteinascidin-743, a new marine natural product with potent antitumour activity on human ovarian carcinoma xenografts
7. High antitumour activity of ET743 against human tumour xenografts from melanoma, non-small-cell lung and ovarian cancer
8. In vitro schedule-dependency of myelotoxicity and cytotoxicity of Ecteinascidin 743 (ET-743)
9. Analysis of Ecteinascidin 743, a new potent marine derived anticancer drug, in human plasma by high-performance liquid chromatography in combination with solid-phase extraction
10. Quantitative determination of Ecteinascidin 743 in human plasma by miniaturized high-performance liquid chromatography coupled with electrospray ionization tandem mass spectrometry
11. 2 in the DNA minor groove by Ecteinascidin 743, a potent antitumor compound from the Caribbean tunicate Ecteinascidia turbinata
12. NMR-Based model of an Ecteinascidin 743-DNA adduct
13. Ecteinascidin 743: A minor groove alkylator that bends DNA toward the major groove
14. Effect of ecteinascidin-743 on the interaction between DNA binding proteins and DNA
15. Interference of transcriptional activation by the antineoplastic drug ecteinascidin-743
16. Ecteinascidin 743, a transcription-targeted chemotherapeutic that inhibits MDR1 activation
17. Ecteinascidin-743 (ET-743), a natural marine compound, with a unique mechanism of action
18. Ecteinascidin 743 induces protein-linked DNA breaks in human colon carcinoma HCT116 cells and is cytotoxic independently of topoisomerase I expression
19. Pharmacokinetics and pharmacodynamics of the novel marine-derived anti-cancer agent Ecteinascidin 743 in a phase I dose-finding study
20. Phase I and pharmacokinetic study of Ecteinascidin-743, a new marine compound, administered as a 24-h continuous infusion in patients with solid tumors
21. Phase I and pharmacokinetic study of Ecteinascidin 743 administered as a 72-h continuous intravenous infusion in patients with solid malignancies
22. Final results of a phase I and pharmacokinetic (PK) study of the marine minor groove binder ET-743 on a daily × 5 schedule
23. A phase I and pharmacokinetic study of ET-743 evaluating a 3-hs intravenous infusion in patients with solid tumors
24. Kinetics of pharmacologic response
25. Dose individualisation in cancer chemotherapy: Pharmacokinetic and pharmacodynamic relationships
26. Cytochrome P450 catalyzed metabolism of Ecteinascidin 743 by rat and human liver microsomes
27. Search for metabolites of ecteinascidin-743, a novel, marine-derived anti-cancer agent, in man